Operator
Good morning, and welcome to the CORE Medics third quarter, 2026 earnings and corporate update conference call. Today's conference call is being recorded. There will be a question and answer session at the end of today's presentation, and instructions on how to ask a question will be given at that time. At this time, I would like to turn the conference over to Dan Ferry from Life Science Advisors. Please go ahead.
Good morning, and welcome to the Corps Medics third quarter 2026 earnings and corporate update comments call. Leading the call today is Joe Tedisco, chairman and chief executive officer of Corps Medics. He is joined by Susan Blum, EVP and chief financial officer. In addition, Liz Hurlburt. Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meeting set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements, other than statements of historical fact, regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial position. Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in Cormetix filings with the SEC, which are available free of charge at the SEC's website or upon request from Cormedics. Cormedics may not actually achieve the goals or plans described in these forward-licking statements, and investors should not place undue reliance on these statements. Cormedics does not intend to update these forward-licking statements, except as required by law. During this call, the company will discuss certain non-GAAP measures of its performance. GAAP to non-GAAP financial reconciliations and supplemental financial information are provided in QuarMedics earnings release and the current report on Form 8K filed with the SEC. This information is also available on the Investor Relations section, QuarMedics' website. In addition, today's discussion includes statements regarding CoreMedic's proposed acquisition of substantially all the assets of Heron Therapeutics, which remain subject to approval by Heron's stockholders, regulatory clearance, and other customary closing conditions. Cormatics has filed a current report on Form 8K describing the proposed transaction in greater detail. Investors are urged to read it and any other relevant documents Cormatics files with the SEC carefully and in their entirety because they contain important information about the proposed transaction. At this time, it is now my pleasure to turn the call over to Joe Tedisco, Chairman and Chief Executive Officer of Cormatics. Joe, please go ahead.
Thanks, Dan. Good morning, everyone, and thank you for joining us on this call. On Monday, we announced the definitive agreement to acquire substantially all of the assets of Heron Therapeutics, encompassing both commercial and pipeline assets that we believe are highly complementary and synergistic with Cormetic's growth strategy in institutional settings of care. As we discussed on Monday, we see four pillars to the strategic rationale for this transaction. First, scale and diversification. The Heron portfolio meaningfully expands our revenue base and further diversifies our revenue mix across acute care and hematology-oncology supportive care and reduces our reliance on DefendCath revenues to drive cash flow and future growth. Heron's portfolio generated approximately $150 million of net product revenue over the trailing 12 months, and we expect the acquired products to contribute approximately $125 to $150 million of revenue for Proforma 2027. Roughly doubling the revenue base for our non-DefendCats portfolio. Second, commercial and operational leverage. We expect to deploy Heron's products through our existing infrastructure, supplemented with a subset of the Heron team, which supports the $45 to $60 million in estimated operating cost synergies that we expect to achieve on an annualized run rate basis by the end of 2027. Third, growth from the UQ care franchise. We view Zinralef in particular as an asset with significant untapped potential as hospitals and surgery centers increasingly adopt non-opioid approaches to post-surgical pain, and together with a Ponvi, which serves the same perioperative call point, represents the fastest-growing parts of the Heron portfolio. And fourth, hematology-oncology supportive care and pipeline optionality. Sinvanti and Sustal both bring an established presence in infusion centers and hematology-oncology clinics, which aligns directly with our planned launch of Rzeo to the prophylaxis indication, if approved by FDA. I also want to highlight how we structure this transaction to align payment with sales performance. Up to $55 million of the consideration is contingent on Zinnerleff achieving net sales milestones in calendar year 2028. And there are additional contingent payments in the form of a royalty above a sales threshold for Sinvanti, Sustol, and any products we launch under the Multiproduct Development Agreement. To that extent, a meaningful portion of what we pay is earned only if the assets perform. We expect the transaction to be immediately accreted to earnings and free cash flow upon closing, which we anticipate in the first quarter of 2027. Subject to Heron stockholder approval, regulatory clearance, and other customary closing conditions. Turning to third quarter performance, we continue to execute on our three core strategic priorities. First, executing on our posted app of commercial strategy for Stencaps. Second, meaningfully advancing our high-value pipeline, highlighted by FDA's acceptance of the SMDA for Roseo for the prophylaxis of invasive fungal disease with priority review. And third, deploying our capital in a disciplined manner to fuel sustainable growth, highlighted by the Heron announcement. We believe this combination of commercial execution, pipeline progression, and strategic capital allocation positions core medics to drive long-term value to shareholders, while building an increasingly diversified and resilient business. For the third quarter, we reported consolidated revenue of $54.5 million, above consensus. And adjusted EBITDA of $3.1 million. And we ended the quarter with $355 million in cash. Importantly, our largest dialysis customers largely maintained a FinCAP utilization through the quarter at the $2.37 add-on in effect for the second half of 2026. Susan will provide more granular details of third quarter financial results. Turning to guidance. Last week, we reaffirmed our full year 2026 revenue guidance. With a range of $325 to $345 million. And today, we're also narrowing our full-year adjusted EBITDA guidance to the top end of the previous range to $130 to $140 million. We also issued a business update last week addressing CMS's release of the ESRD PPS final rule for 2027, as well as comments made by the CFO of a large dialysis organization related to the 2027 post-Adapa add-on payment for DefendCast. While the ESRD final rule established a post-Adapa add-on of $8.32 for the first quarter of 2027, which is within our previously guided range, CMS also finalized the new methodology to calculate add-on payments, whereby they will be reset quarterly. Because the quarterly add-on incorporates recent utilization and pricing data, its trajectory quarter-to-quarter depends on information that only core medics can report to CMS. We have not shared that data with any customer or third party, and we believe third-party projections of the quarterly path are subject to significant uncertainty. As we disclosed in our announcement, this new quarterly mechanism will result in an overall average reimbursement to customers that is lower than the $8.32 over the course of the year. However, based on our review of our own pricing and utilization data, we currently expect the add-on in each quarter of 2027 to exceed the current $2.37, and we currently estimate the full-year average to be at least double that current rate. After a decline from Q1 to Q2, we expect the add-on in Q3 and or Q4 of 2027 to be higher than the second quarter, in each case subject to how CMS applies its methodology, including certain utilization and pricing data in its calculations. Put simply, the low-ass add-on we currently expect to send CAS to see in 2027 is higher than our current rate customers receive today. And our LDO and MDO customers have largely maintained utilization at today's current rate in the third quarter. We are currently engaged in conversations with customers around how to structure DefendCast pricing that tracks the quarterly add-on adjustments with the goal of keeping fee-for-service patients on therapy throughout the year. We're also actively working to secure separate payment for DefendCast from top Medicare Advantage plans. As a result, we will not be in a position to rely on any 2027 revenue guidance for DefendCast until we have visibility into both customer pricing and expected utilization for Medicare fee-for-service patients, as well as possible upside for Medicare Advantage. In that regard, we are deferring 2027 DefendCast guidance at this time and anticipate being able to update investors in early 2027. We continue to believe that Medicare Advantage represents a meaningful long-term growth avenue for DefendCast and the best opportunity for the product to have a sustainable value following the ending of the post-ADAPA add-on in 2029. DefendCast's clinical value and its potential for meaningful downstream cost savings continue to be supported by a growing body of real-world evidence that our partners are publishing, and I'm proud of the data presentations that took place this past October at the American Society of Nephrology's Kidney Week and at ID Week. Turning to our pipeline, we announced in October that the SMDA for Rezeo and prophylaxis was accepted for FDA review with priority review status and a target action date from the FDA in the first quarter of 2027. As a reminder, submission was conducted by our global partner, Mundy Pharma, following positive clinical trial results from the RESPECT study, a Phase III clinical study evaluating Rezeo for the prophylaxis of invasive fungal disease in adult immunosuppressed patients undergoing allogeneic bone and marrow transplant. We're actively preparing for promotional efforts for Roseo in this new indication, and if approved by FDA, would anticipate commencement of promotional efforts in the second half of 2027. Finally, with respect to our Phase III TPN study for DEFENDCAF, despite engagement of new study sites and the FDA approval of a protocol amendment that narrows certain exclusion criteria, study enrollment continues to track meaningfully behind our original estimated timelines. Given the established safety profile for FENCAS and demonstrated efficacy in its currently approved indication, we are evaluating potential alternative pathways to pursue approval with FDA should enrollment not accelerate in the next one to two months. We expect to make a decision on the strategy for TPN prior to our next quarterly update call. I'd like to now turn the call over to Susan to discuss the company's third quarter financial results and financial position. Susan?
Thank you, Joe, and good morning, everyone. As a reminder, the Malenta acquisition closed on August 29, 2025. As a result, the third quarter of 2026 includes a full quarter of Malenta operations compared with the third quarter of 2025, which only has one month of Malenta's operations. This difference affects the year-over-year comparison of both revenue and expenses in a meaningful way. We also filed our form. And I encourage investors to review it for additional information regarding our third quarter and near-to-date results, financial position, and related disclosures. Overall, our third quarter results reflect the anticipated transition of DefendCast into the post-Adapa reimbursement environment, continued contributions from the broader product portfolio, and disciplined management of our operating expense space. Now turning to the drivers, consolidated revenue for the third quarter of 2026, Compared with 104.5 million dollars, compared with 104.5 million dollars, compared with 104.5 million dollars. Thank you.
To acquire the heroin assets, along with a strong balance sheet and access to additional non-deluged capital from our Pharmacom Terminal facility, I'm excited about the potential for the organization. Cormedics is building a leading, diversified, commercial platform across institutional settings of care. We have a portfolio of complementary assets utilized in hospitals, infusion clinics, and hematology-oncology clinics, with a commercial and medical footprint that spans across those therapeutic settings. Our near-term priorities are clear. Closing the heroin transaction and capturing synergies, navigating the FENCAS through the 2027 quarterly add-on framework while pursuing Medicare Advantage, and preparing for potential commercialization of Reseo for an expanded indication of prophylaxis. Over time, we will continue to evaluate additional assets that are synergistic with our commercial and medical footprint with the same discipline we apply to Melinta and heroin. At this time, I'm happy to open up for questions.
Operator
We will now begin the question and answer session. To ask a question, you may press star, then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star and then two. Our first question comes from Les Saluski with Oppenheimer. Please go ahead.
Hey, Moderator, it seems like Les is having a technical problem. Do you want to move to the next and then come back?
Operator
Yes. In the next question – I'm sorry.
Okay, I'll repeat. Sorry about that. So, I have three questions. So, Joe, you noted that Cormedics will be solely in control of providing utilization rates to CMS for the add-on calculations. Is there a factor of selectivity or subgroup or certain timeframes of utilization that can be submitted by you, or is it broad? And then second, on Medicare Advantage, what's the main hurdle to getting the first contract signed and how quickly could get patients utilized following on? And then lastly, what's driving the slow TPN enrollment? Thank you.
Okay. Three good questions, Les. On the first one, in terms of the data that gets, well, we say only we are in control of the data that gets reported to CMS because it's our sales data. And the way that CMS calculates ASP for the purpose of calculating the add-on, it's based on the timing of when, let's say, rebates are paid as opposed to when they're accrued. So there may not necessarily be alignment between when we report net price in our earnings versus when it hits ASP. And a lot of these contracts have longer-term volume incentive rebates. Where perhaps you're paying those rebates, you know, on a very delayed timeframe, and it ends up ultimately hitting ASP in a different period than what an outside third party might just look at financials and expect it to hit. So that's kind of the disconnect that we wanted to highlight with how CMS calculates that add-on. For Medicare Advantage, you know, I am still, as I said last time, partially optimistic that we can get something done before the end of this year. I think I likened the example of working with an MA plan to trying to turn an aircraft carrier, which is slow. I would say that, you know, I believe that we have a contractual framework that is It's not largely final, but for the M.A. plan, you know, agreeing to how this is going to be operationalized. And I think those are still the hurdles that our team is actively working, at least with the largest plans through those specifics. So, you know, hopefully we'll be able to provide an update before the end of the year, and that's what our team is working on. You know, on TPN, you know, I went with comment. It's not a shortage. It's not a change in the market opportunity. It's an ability for these types of patients to participate in a clinical study. Do you mind, guys?
Yeah, so just to piggyback on what Joe said, there are a limited number of subjects actually eligible to participate in a study, right, not representative of the TPN market, but they're really complex patients. There are a lot of underlying conditions that make it challenging to participate. Intestinal failure, cancers, things like that make it difficult to adhere to a study's schedule. Frequently, antibiotics or antifungals are used prophylactically, and obviously, it's very challenging to be able to see a signal for DEFEND-CAT that patients need to be on that from a standard of care standpoint. And lastly, we have added quite a few sites here in the U.S. as well as in Turkey, but the number of patients that are attached to it. Academic medical center that has the infrastructure to run a clinical trial versus those that are seen in community practices or perhaps don't live near a site. We have extensive work done, I'd say, extensive work done with patient advocacy groups and with all of our investigators to continue identifying subjects that are eligible. But the logistics of running a study in this patient population are proving to be rather challenging right now.
Noted. Thank you. And I apologize for the technical issues.
That's okay. Thanks, Wes.
Operator
And the next question comes from Leo Timoshev with RBC. Please go ahead.
Hi, thanks for taking our question. This is Xander on for Leo, and I know you commented on a lot of this already, but I'm just wondering, you know, if you can expand on the outlook for 27, and what do you see as, you know, the most supportive and constructive factors for deaf and cats going into this, and, you know, what areas are going to require a little bit more careful navigation? Thank you.
Thanks, Andrew. I mean, as we said in the script, we're really not in a position to provide guidance right now for DefendCast for 2027. There are pushes and pulls. You know, as we said in the script as well, we think the add-on on average is going to be lower than 832. That needs to be taken into account in terms of how we essentially price the product quarter to quarter, specifically for fee-for-service patients. You know, the poll, we're looking for the Medicare Advantage patients to Medicare Advantage contracting to both pull up number of patients as well as pricing. And once we have better visibility of that. We hope to provide guidance on where we think revenue for ExtentCats can land in 2027. We'll also, at that time, provide overall guidance for the company for 2027. Right now, what we're comfortable with is what we've put out for the heroin acquisition and what we'll update likely in the first quarter.
Thank you. Really appreciate the context.
Operator
And the next question comes from Brandon Foulkes with HC Wainwright. Please go ahead.
Hi, thanks for saying my questions, and congrats on managing through the quarter. Maybe just two from me. You know, you talked about kind of uncertainty for the dialysis operators. Just given how traditionally they do take time. You know, to move. How much of a risk is that uncertainty just in terms of kind of protocols and things that they may want to put in? You know, what can you do to provide volume certainty to the operators in 2027? Is that sort of how you're looking at it? And then ASP may be the variable in terms of Cormedix's reporting. And then that's just the one for me. Yeah, I think that's it for now, because I think that's probably quite – thank you.
I'm sorry, Brandon. I want to clarify, because I want to make sure that you understood what I had said. When I was talking about the time to move and then being slow, I was referring to the Medicare Advantage plan, which is the payer. And, you know, large organizations were trying to do something that's never been done before, which is take something that's traditionally inside the bundle and contract it out to be separately reimbursed. We have a compelling case for that. This is a preventative. This takes costs out of the system. It's a strong form of economic benefit to the MA plan to actually have payment follow the product instead of bundleizing. So that's largely the argument around MA. When it comes to the dialysis operators and protocols, specifically our three largest customers, being Fresenius, U.S. Renal Care, and IRC, those protocols are already in place, and to our knowledge, nothing has been altered in the last couple of months.
And so can they just, just to follow on, you know, are they in a position to dial up utilization and dial it down on a quarterly basis? Just any color in terms of that element, just so I can understand kind of the rules on 27.
Look, I don't know if I think of it that way, right? If you have a patient that is stable on a preventative measure, I would expect that. Either they stay on that, or if they're going to move, it's not going to be quarter to quarter for that patient. I think that would be irresponsible to make changes quarter to quarter like that. The opportunity with Medicare Advantage would be they do have the ability to do a benefits verification for their patients, understand the payer dynamic, and then transition certain patients longer term to that therapy.
Great, thanks. And then maybe just one follow-up. You know, obviously, 1Q27, you know, there's going to be a lot going on with Rosario and the Heron closed. Can you just talk about your expectations for Heron in terms of damping kind of what you want to do with those products? You know, how long does that take? Just setting – I know you can't talk too much in specifics right now, but maybe just setting the timeframe in terms of when we see the Cormetix impact on the Heron products post-close.
Yeah, look, we've put out a revenue range for next year, and a lot of that, the variability in that range isn't as much related to what I think we can do immediately with kind of our fingerprint, as opposed to the external dynamics, certainly related to Sinvante, the situation with Azzerty, and how that litigation progresses and any potential launch at risk by Azzerty of a competing branded product. You know, all of that kind of factors into that range, but we're hoping to close in the first quarter. We have specifically around zero left ideas that we think for things that, you know, based on our research that we can maybe pivot on or do a little bit differently. I don't know, you know, I don't want to commit today to how long that will take to either implement or see results, but, you know, certainly we're excited about the assets and the deal, you know, that we announced. Great. Thank you very much.
Operator
And the next question comes from Jason Butler with CitizenJMP. Please go ahead.
Hi, thanks for taking the questions. Just a couple outside of DefendCap. First, can you talk a little bit more about what you're doing to prepare for the Rosio profi launch? What is awareness of the product and the profi data now among potential prescribers? Second, can you just talk a little bit more about the growth potential for Zinrolav, one of the products you just got from Heron? Obviously, a large TAM, but, you know, what are your thoughts here on commercial strategy and what you guys can do to drive growth? And then just lastly, can you just give us thoughts on the quarter for the base business for Melinter and the growth potential that's still in that portfolio?
Okay, I'm going to actually take the second and third question first, and then Liz will comment on the prophylaxis launch press. Look, in terms of the growth opportunity for Zim, we do see it as a large market opportunity, even if you just look at the other non-opioid, you know, Long-acting, you pay the cane market that's out there. It's a sizable market opportunity. Where Zinnerweck is currently being used is almost exclusively in ortho. The label is much broader than that. We do think there's an opportunity for expansion. I'm not going to put a number today around where we think we can grow it to, but we do think there's potential upside for things that we can do there. Um, like on the base business revenue, and I think you're, you're, you're largely talking about, you know, baby mirror medicine, commercial or active, uh, those are durable, durable-ish Certainly when you're talking about baby mirror medicine, uh, you know, we do see a periodically low single digit growth on those products, but it does also kind of vary a little bit quarter to quarter institution to institution, um, you know, or backdives and, uh, commercial, Versa, which are the Red Advancement products, did contract this year after Generic Dalvance launched last year. We're looking at somewhat of an increased promotional activity towards the back part of next year once the kind of profit arbitrage for the generics diminishes a little bit in the back part of next year. But, you know, that's how I would view the base business. Then you have Topol and Bextello that are pretty much flat. Liz, do you want to comment on Rizeo?
Sure. So as we prepped for Rizeo Profi launch, I'd say we have a really cross-functional approach to preparing. We're certainly leveraging a very strong commercial infrastructure, but working closely with medical and market access as well. I think right now we're really focused on a few key priorities. We're refining the market segmentation and the customer targeting, really advancing the market access strategy, and preparing the field for this engagement and ensuring that we've got alignment across all of our functions here. And our medical team and some of the market access team is already working on building a presence and relationships with the bone marrow transplant centers and those institutional markets. Thank you. It's to ensure that we're not just prepared for a successful lunch, but that we are able to sustain the business and really maximize the long-term value that we think of.
Operator
And the next question comes from Sergey Bellinger with Needham & Company. Please go ahead.
Hi, good morning. I guess three questions for us, too. First, on the LDL pilot program, any update there on how much it contributed to the third quarter and whether there's plans to expand beyond a pilot? Secondly, on DEFNCAT, you reported $17.2 million in sales this quarter. $5 million of it was from a sales allowance charge. Should we think as a $12 million sales base as the level going forward for 4Q and on which you'll grow from in 2027? And then lastly, on Roseo, Any outlook on what the label could look like for the product now that the review is underway and the priority review has been granted? Thank you. All right.
Thanks. Look, the LDO pilot, we're really excited to get that contract done and get that finally over the finish line and have them implement, but we have not had any kind of repeat ordering from there. We continue to engage, and we're hopeful that we can perhaps drive something next year with engagement with Medicare Advantage, but right now, we don't have any real visibility into increased adoption or the results of that pilot. So, good question about the FENCAP in the fourth quarter. I'd say, you know, tentatively, yes. I think it could be a little bit of a notch up, but that's probably the right way to look at it. You know, from a pricing standpoint, we want the volume to stay consistent and then roll into next year with some higher pricing, at least for that kind of what we'll call base business fee-for-service patients that we're looking to preserve. Look, on the Roseo label, we're not going to comment until we get feedback from FDA. You know, the results are out there for the clinical study, and Monday Pharma is in control of that regulatory process, and we're providing whatever support we can to them in that regard.
Operator
This concludes our question and answer session. The conference has concluded. Thank you for attending today's presentation. You may now disconnect.